Melatonin

Melatonin (N-acetyl-5-methoxytryptamine) is a tryptophan-derived indoleamine neurohormone synthesized primarily in the pineal gland under the control of the suprachiasmatic nucleus (SCN) circadian clock. Discovered by Aaron Lerner in 1958 and structurally characterized through skin blanching activity in frogs, melatonin was initially understood solely as a pineal hormone encoding photoperiod information for seasonal reproductive control. Over subsequent decades, its functions have expanded to encompass central circadian rhythm entrainment, mitochondrial antioxidant protection, immune modulation, anti-inflammatory signaling, and neuroprotection. The compound is found across virtually all life forms including unicellular algae, where it may have originally served an antioxidant function, and is synthesized locally in the gut, retina, skin, and immune cells in addition to the pineal gland. Melatonin from the pineal gland follows a strict circadian pattern with 10-fold increases at night, peaking between 2 and 4 AM, with complete suppression upon light exposure. This nocturnal surge is the body's primary endocrine signal of darkness and encodes circadian phase information for every tissue in the body.

The chronobiotic effects of melatonin are mediated by two high-affinity G-protein coupled receptors, MT1 and MT2 (encoded by MTNR1A and MTNR1B), expressed at highest density in SCN neurons. MT1 receptors couple to Gi proteins to suppress adenylyl cyclase activity, reducing cAMP levels in SCN neurons and thereby suppressing their firing rate during the biological night. MT2 receptors additionally mediate phase-shifting of the circadian oscillator through PKC and inositol phosphate signaling pathways. The result is that exogenous melatonin, taken in advance of the desired sleep time, can advance or delay the circadian clock phase by 1 to 3 hours depending on timing relative to the current circadian phase. This property makes melatonin the most effective pharmacological agent for treating circadian rhythm disorders including delayed sleep phase syndrome, jet lag, and shift work sleep disorder. Unlike hypnotic agents that suppress the CNS broadly, melatonin produces sleep by signaling through the normal chronobiological pathway, making it physiologically appropriate and free of the dependency and withdrawal effects associated with benzodiazepines and z-drugs.

Beyond its circadian function, melatonin is an extraordinarily potent antioxidant through multiple mechanisms. It directly scavenges hydroxyl radicals, peroxynitrite, singlet oxygen, and hypochlorous acid at rate constants that equal or exceed the fastest known enzymatic scavengers. Uniquely, melatonin's oxidation products (cyclic 3-hydroxymelatonin, AFMK, and AMK) are themselves potent antioxidants, creating a radical scavenging cascade where a single melatonin molecule can neutralize 4 to 10 reactive species sequentially without enzyme regeneration. This cascade mechanism, combined with melatonin's ability to concentrate in mitochondria at concentrations 100-fold above plasma through as-yet incompletely characterized active transport, makes it particularly effective at protecting the inner mitochondrial membrane from lipid peroxidation during the intense oxidative phosphorylation that occurs during wakefulness and physical activity. Melatonin also induces the expression of SOD2 and catalase at the transcriptional level, amplifying cellular antioxidant capacity beyond direct radical scavenging.

The clinical evidence for melatonin spans three distinct domains: sleep and circadian biology, neuroprotection and anti-aging, and emerging cardiovascular and metabolic benefits. In sleep medicine, melatonin's chronobiotic effects are established by meta-analyses covering hundreds of RCTs in diverse populations. For neuroprotection, the mechanistic rationale is compelling but human clinical translation remains ongoing; animal studies consistently show neuroprotection in Alzheimer's, Parkinson's, and Huntington's disease models through GSK3B inhibition, NLRP3 suppression, and mitochondrial antioxidant mechanisms. Clinical trials in Alzheimer's disease patients show improvements in sundowning behavior and sleep-wake cycle stabilization at doses of 2 to 10 mg per night, with some evidence for slowed cognitive decline in early-stage patients. In cardiovascular medicine, melatonin supplementation reduces blood pressure in non-dipping hypertension (the inability to reduce BP during sleep) by an average of 6 mmHg systolic and 4 mmHg diastolic in RCTs, through circadian clock normalization and direct antioxidant protection of vascular endothelium.

Mechanism of Action

MT1 and MT2 Receptor Signaling and Circadian Entrainment

Melatonin exerts its chronobiotic effects through two G-protein coupled receptors, MT1 (MTNR1A) and MT2 (MTNR1B), expressed at highest density in the suprachiasmatic nucleus (SCN) but also in numerous peripheral tissues including liver, adipose tissue, pancreatic islets, and vascular smooth muscle. MT1 receptors couple primarily to Gi proteins, suppressing adenylyl cyclase activity and reducing cAMP levels in SCN neurons during the biological night. This reduced cAMP suppresses PKA activity and decreases the firing rate of SCN neurons that would otherwise maintain the wake signal. MT2 receptors signal through Gq and additional pathways including PKC activation to produce phase-shifting effects on the molecular clock. The CLOCK-BMAL1 heterodimer drives transcription of clock-controlled genes during the circadian day, while PER1/PER2 and CRY1/CRY2 proteins accumulate to inhibit CLOCK-BMAL1 in the negative feedback loop. Melatonin’s receptor-mediated effects on SCN firing rate and cAMP signaling modulate the phase and amplitude of this molecular oscillator, providing the environmental night signal that anchors the clock to local time. Exogenous melatonin taken at specific circadian phases can advance or delay the clock by 1 to 3 hours, making it clinically useful for phase-shifting disorders. The direction and magnitude of phase shifting depends on the current circadian phase at which melatonin is administered, described by the melatonin phase response curve.

Direct Antioxidant Cascade and Mitochondrial Protection

Melatonin is a non-enzymatic antioxidant with reaction rate constants for hydroxyl radical scavenging (kOH = 1.1 x 10^10 M^-1s^-1) that rival enzymatic scavengers. Its molecular structure, with an indoleamine ring and electron-donating methoxy substituent, enables direct electron donation to radical species. Unique to melatonin is its antioxidant cascade: when melatonin scavenges a hydroxyl radical, the product is cyclic 3-hydroxymelatonin, which is itself an antioxidant capable of scavenging two additional reactive oxygen species. Further oxidation produces AFMK (N1-acetyl-N2-formyl-5-methoxykynuramine) and then AMK (N1-acetyl-5-methoxykynuramine), both of which are additional antioxidants. This cascade allows a single melatonin molecule to neutralize 4 to 10 reactive species sequentially, providing antioxidant efficiency far exceeding simple radical scavengers. In mitochondria, where melatonin concentrates at levels 100-fold above plasma through mechanisms involving PEPT1/2 transporters in the inner membrane, this cascade provides targeted protection against the superoxide and hydroxyl radicals generated by Complexes I and III during electron transport. Mitochondrial membrane potential is better preserved, cytochrome c release is reduced, and ATP synthesis capacity is maintained under oxidative stress in melatonin-supplemented tissues.

SOD2 Induction and Antioxidant Enzyme Amplification

In addition to direct scavenging, melatonin amplifies cellular antioxidant capacity by transcriptionally inducing SOD2, catalase (CAT), and glutathione peroxidase (GPX1). The mechanism involves melatonin activation of NRF2 (nuclear factor erythroid 2-related factor 2), the master transcriptional regulator of antioxidant response element (ARE)-driven gene expression. Melatonin activates NRF2 by modifying KEAP1 cysteine residues through its reactive metabolites, releasing NRF2 from KEAP1-mediated proteasomal targeting and allowing NRF2 nuclear translocation. Nuclear NRF2 binds ARE sequences in the SOD2, CAT, and GPX1 gene promoters, driving sustained transcriptional upregulation of these antioxidant enzymes. This NRF2-mediated enzyme induction operates on a timescale of hours and provides durable antioxidant protection that persists beyond the half-life of melatonin itself. The combination of rapid direct scavenging and slower enzyme-mediated amplification gives melatonin a layered antioxidant mechanism that is particularly effective under conditions of sustained oxidative stress, as occurs in aging mitochondria, ischemia-reperfusion injury, and chronic neuroinflammation.

GSK3B Inhibition and Neuroprotection

Melatonin inhibits glycogen synthase kinase 3 beta (GSK3B) through the PI3K-AKT signaling pathway downstream of MT1 and MT2 receptor activation. AKT, activated by receptor-stimulated PI3K, phosphorylates GSK3B at Ser9, converting it from its constitutively active to inactive form. GSK3B is a multifunctional serine/threonine kinase that phosphorylates tau at Alzheimer’s disease-relevant sites including Thr181, Thr231, Ser396, and Ser404, contributing to the formation of neurofibrillary tangles. GSK3B also phosphorylates APP (amyloid precursor protein) to direct its processing toward the amyloidogenic pathway, and phosphorylates the BMAL1 component of the circadian clock, disrupting circadian gene expression in neurons. Melatonin’s GSK3B inhibition addresses all three of these pathological processes simultaneously: reducing tau hyperphosphorylation, decreasing amyloidogenic APP processing, and restoring circadian gene expression in affected neurons. In triple-transgenic Alzheimer’s mouse models, melatonin supplementation for 6 months significantly reduces tau phosphorylation at GSK3B target sites, reduces amyloid plaque deposition, and partially rescues spatial navigation memory, demonstrating that pharmacological GSK3B inhibition through MT1/MT2 receptor activation produces measurable disease-modifying effects in animal models of AD.

Epigenetic Modulation and SIRT1 Activation

Melatonin activates SIRT1 deacetylase activity through two converging mechanisms. First, melatonin’s antioxidant effects reduce NAD+ consumption by PARP1, which is activated by oxidative DNA damage. This preservation of NAD+ increases the NAD+/NADH ratio and enhances SIRT1’s NAD+-dependent deacetylase activity. Second, melatonin directly activates SIRT1 through MT1 receptor-mediated reduction of cAMP, which reduces PKA-mediated SIRT1 inhibitory phosphorylation. Activated SIRT1 then deacetylates FOXO3 transcription factor, promoting its nuclear localization and target gene transactivation. FOXO3 target genes include ATG5, ATG7, BECN1, and other autophagy execution factors, linking melatonin signaling to the induction of autophagic flux in neural tissues. This SIRT1-FOXO3-autophagy axis provides a mechanism for melatonin to promote the clearance of protein aggregates that accumulate in aging neurons, complementing its direct antioxidant and anti-inflammatory actions with proteostasis maintenance.

Clinical Evidence

Sleep Disorders and Circadian Rhythm Disturbances

The clinical evidence for melatonin in sleep medicine is the most extensive of any natural supplement in this category. A systematic review and meta-analysis by Ferracioli-Oda et al. (2013, PLOS ONE) of 19 studies (n=1,683) found that melatonin significantly decreased sleep onset latency by 7.06 minutes, increased total sleep time by 8.25 minutes, and improved overall sleep quality compared to placebo. Effects were consistent across age groups but most pronounced in patients with circadian rhythm disorders. In jet lag specifically, Herxheimer and Petrie (Cochrane Review, 2002) analyzing 10 RCTs found melatonin effective at reducing jet lag severity when taken at destination bedtime, with stronger effects for eastward travel of 5 or more time zones. For shift work disorder, melatonin improves daytime sleep quality when taken before planned daytime sleep periods, with clinical studies showing 30 to 45 minute increases in total daytime sleep time.

Alzheimer Disease and Neurodegeneration

Clinical evidence for melatonin neuroprotection in Alzheimer’s disease comes primarily from studies addressing circadian and sleep aspects of the disease. A 2011 Cochrane Review (Jansen et al.) found that melatonin improved sundowning behavior and sleep-wake cycle stability in mild-to-moderate AD patients at doses of 2 to 10 mg per night. A 24-month randomized trial (Cardinali et al., 2012) in mild cognitive impairment patients found that 3 to 9 mg extended-release melatonin nightly significantly slowed decline on cognitive performance measures and reduced caregiver burden compared to sleep hygiene advice alone. The circadian stabilization provided by melatonin may have disease-modifying implications beyond symptom relief, as disrupted circadian rhythms accelerate amyloid-beta accumulation through reduced glymphatic clearance during disordered sleep.

Cardiovascular Protection

A meta-analysis by Grossman et al. (2011) found that 2 mg extended-release melatonin reduced nocturnal blood pressure by 6.1/3.5 mmHg in non-dipping hypertensive patients. A separate meta-analysis by Xu et al. (2015) pooling 20 trials found that melatonin supplementation significantly reduced LDL cholesterol (mean reduction 9.5 mg/dL) and increased HDL cholesterol, effects likely mediated by circadian clock normalization in hepatic lipid metabolism and antioxidant protection of LDL particles. In patients with acute myocardial infarction, studies of intravenous melatonin at reperfusion demonstrated significant reductions in cardiac enzyme release (CK-MB, troponin I) and improvement in left ventricular function at 30 days, consistent with the anti-NLRP3 and mitochondrial protective mechanisms demonstrated in preclinical models.

Dosing Guidance

For sleep onset and circadian rhythm disorders, immediate-release melatonin at 0.5 to 3 mg taken 30 to 60 minutes before the target bedtime is the evidence-based approach. Doses above 3 mg do not confer proportionally greater sleep benefits and increase the risk of morning grogginess. For sleep maintenance, extended-release formulations at 2 mg are preferred and are approved in the EU for adults over 55. For jet lag, 0.5 to 5 mg at the destination bedtime starting on the travel day and continued for 3 to 5 nights is evidence-based. For circadian phase-shifting in delayed sleep phase syndrome, very low doses (0.5 mg) taken 4 to 6 hours before the current sleep time are more effective at advancing the clock than larger doses at bedtime. For neuroprotective applications in Alzheimer’s disease, 5 to 10 mg of extended-release melatonin nightly has been studied in clinical trials. For anti-inflammatory and antioxidant effects relevant to cardiovascular and metabolic health, pharmacological doses of 5 to 20 mg have been used in research settings.